The ALS CellCelector platform is used to screen and isolate ASC therapeutic antibodies derived from XenoMouse-immunized single B cells. It is believed that this platform can thus be leveraged to characterize human ASCs harvested from peripheral blood of patients undergoing an active disease or expanded to ASCs from other animal or transgenic species. Furthermore, expanding assays (such as antibody competition, epitope binning, receptor-ligand blocking) and using the seven-color imaging capabilities will be necessary steps to realize the full capabilities of the CellCelector platform.
ALS CellCelector platform can be used to identify and isolate B-cells specific to a therapeutic target in antibody discovery. This technology can be readily adapted to the discovery of antibodies to other therapeutic targets.
<Photos>
